For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Bronchiectasis is a long-term lung condition where the airways stay widened and inflamed. These airway changes make it harder to breathe and clear mucus. People with bronchiectasis live with a ...

A multidisciplinary program for bronchiectasis and pulmonary NTM disease reduced patient exacerbations by 36% per quarter.

Please provide your email address to receive an email when new articles are posted on . Patients in this subgroup participated in the phase 3 ASPEN trial. Brensocatib given as 10 mg or 25 mg performed ...

Miami (November 11, 2025) – Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease report differences in symptoms, mental ...

New registry data show bronchiectasis affects multiple alpha-1 antitrypsin deficiency genotypes, not just Pi*ZZ.

A simple at-home program with daily exercise, airway clearance, and nurse support helps patients breathe easier, offering new hope for millions living with this chronic lung disease. Study: Role of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. This study cohort was made up of 71.3% U.K. patients ...

Miami (July 31, 2025) – The Bronchiectasis and NTM Association joins other global patient advocacy organizations, professional societies, and lung health experts for the third annual World NTM ...